Bold Therapeutics updates stakeholders on the clinical advancement of BOLD-100 during the BIO-Europe conference, focusing on its proprietary metallotherapeutics pipeline.
Bold Therapeutics announces corporate and BOLD-100 updates at BIO-Europe, but no financial results or guidance are disclosed.
Vancouver-based Bold Therapeutics is showcasing corporate milestones and clinical progress for its lead candidate, BOLD-100, at the BIO-Europe conference. The clinical-stage biopharmaceutical firm aims to highlight its novel metallotherapeutics platform to international investors and industry partners.
The company is presenting corporate milestones and clinical advancement data regarding its lead therapeutic candidate, BOLD-100.